Product Code: IRTNTR30886
About this market
The global colorectal cancer therapeutics market is largely dominated by monotherapy drugs, including targeted therapies and immunotherapies. However, the combination of these monotherapy drugs with chemotherapy or other therapeutics also increases the therapeutic value. The combination of drugs helps in overcoming the limitations of each therapeutic and increases the overall outcome in the treatment of colorectal cancer. Furthermore, the combination of therapies with or without surgery can be used to reduce the spreading of the disease and temporarily shrink a cancerous tumor. Moreover, the combination therapy that contains two or more number of therapeutics is useful to achieve an additive or synergistic effect with low doses of combinational therapeutics. Technavio's analysts have predicted that the colorectal cancer therapeutics market will register a CAGR of almost 3% by 2023.
Market Overview
Rising population with risk factors of colorectal cancer
The incidence of colorectal cancer is increasing owing to the risk factors such as the increasing geriatric population, inflammatory diseases, genetic syndromes, and changes in lifestyle. Hence, an increase in the number of patients with these risk factors is expected to increase the development of colorectal cancer. This, in turn, is expected to aid in the use of available therapeutics, which will drive the growth of the global colorectal cancer therapeutics market during the forecast period.
Patent expiration of novel therapeutics
The pharmaceutical companies sell their innovator products, especially biologics, at a high price until their patent expiration. The expiration of patents and other intellectual property rights of therapeutics are likely to hamper the growth of the global colorectal cancer therapeutics market during the forecast period.
For the detailed list of factors that will drive and challenge the growth of the colorectal cancer therapeutics market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fairly concentrated and with the presence of limited vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.
TABLE OF CONTENTS
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
- 2.1. Preface
- 2.2. Preface
- 2.3. Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
PART 06: MARKET SEGMENTATION BY TYPE
- Market segmentation by type
- Comparison by type
- Targeted therapy - Market size and forecast 2018-2023
- Immunotherapy - Market size and forecast 2018-2023
- Chemotherapy - Market size and forecast 2018-2023
- Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2018-2023
- Europe - Market size and forecast 2018-2023
- Asia - Market size and forecast 2018-2023
- ROW - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
- Market drivers
- Market challenges
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
- Overview
- Landscape disruption
- Competitive scenario
PART 13: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd
- Merck & Co., Inc.
- Sanofi
PART 14: APPENDIX
- Research methodology
- List of abbreviations
PART 15: EXPLORE TECHNAVIO
List of Exhibits
- Exhibit 01: Global oncology therapeutics market
- Exhibit 02: Segments of global oncology therapeutics market
- Exhibit 03: Market characteristics
- Exhibit 04: Market segments
- Exhibit 05: Market definition - Inclusions and exclusions checklist
- Exhibit 06: Market size 2018
- Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
- Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
- Exhibit 09: Five forces analysis 2018
- Exhibit 10: Five forces analysis 2023
- Exhibit 11: Bargaining power of buyers
- Exhibit 12: Bargaining power of suppliers
- Exhibit 13: Threat of new entrants
- Exhibit 14: Threat of substitutes
- Exhibit 15: Threat of rivalry
- Exhibit 16: Market condition - Five forces 2018
- Exhibit 17: Type - Market share 2018-2023 (%)
- Exhibit 18: Comparison by type
- Exhibit 19: Targeted therapy - Market size and forecast 2018-2023 ($ millions)
- Exhibit 20: Targeted therapy - Year-over-year growth 2019-2023 (%)
- Exhibit 21: Targeted therapies in Phase III for colorectal cancer treatment
- Exhibit 22: Immunotherapy - Market size and forecast 2018-2023 ($ millions)
- Exhibit 23: Immunotherapy - Year-over-year growth 2019-2023 (%)
- Exhibit 24: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
- Exhibit 25: Chemotherapy - Year-over-year growth 2019-2023 (%)
- Exhibit 26: Market opportunity by type
- Exhibit 27: Customer landscape
- Exhibit 28: Market share by geography 2018-2023 (%)
- Exhibit 29: Geographic comparison
- Exhibit 30: North America - Market size and forecast 2018-2023 ($ millions)
- Exhibit 31: Colorectal cancer rate based on gender in US 2015
- Exhibit 32: North America - Year-over-year growth 2019-2023 (%)
- Exhibit 33: Top 3 countries in North America
- Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
- Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
- Exhibit 36: Top 3 countries in Europe
- Exhibit 37: Asia - Market size and forecast 2018-2023 ($ millions)
- Exhibit 38: Asia - Year-over-year growth 2019-2023 (%)
- Exhibit 39: Top 3 countries in Asia
- Exhibit 40: ROW - Market size and forecast 2018-2023 ($ millions)
- Exhibit 41: ROW - Year-over-year growth 2019-2023 (%)
- Exhibit 42: Top 3 countries in ROW
- Exhibit 43: Key leading countries
- Exhibit 44: Market opportunity
- Exhibit 45: Rate of colorectal cancer by age in the US
- Exhibit 46: Global geriatric population
- Exhibit 47: Combination therapies for colorectal cancer treatment
- Exhibit 48: Late-stage combination therapies for treatment of colorectal cancer
- Exhibit 49: Estimated patent expiry dates of a few therapeutics used for colorectal cancer treatment
- Exhibit 50: Impact of drivers and challenges
- Exhibit 51: Some of the kinase inhibitors under development for colorectal cancer treatment
- Exhibit 52: Vendor landscape
- Exhibit 53: Landscape disruption
- Exhibit 54: Vendors covered
- Exhibit 55: Vendor classification
- Exhibit 56: Market positioning of vendors
- Exhibit 57: Bristol-Myers Squibb Company - Vendor overview
- Exhibit 58: Bristol-Myers Squibb Company - Business segments
- Exhibit 59: Bristol-Myers Squibb Company - Organizational developments
- Exhibit 60: Bristol-Myers Squibb Company - Geographic focus
- Exhibit 61: Bristol-Myers Squibb Company - Key offerings
- Exhibit 62: Bristol-Myers Squibb Company - Key customers
- Exhibit 63: Eli Lilly and Company - Vendor overview
- Exhibit 64: Eli Lilly and Company - Business segments
- Exhibit 65: Eli Lilly and Company - Organizational developments
- Exhibit 66: Eli Lilly and Company - Geographic focus
- Exhibit 67: Eli Lilly and Company - Segment focus
- Exhibit 68: Eli Lilly and Company - Key offerings
- Exhibit 69: Eli Lilly and Company - Key customers
- Exhibit 70: F. Hoffmann-La Roche Ltd - Vendor overview
- Exhibit 71: F. Hoffmann-La Roche Ltd - Business segments
- Exhibit 72: F. Hoffmann-La Roche Ltd - Organizational developments
- Exhibit 73: F. Hoffmann-La Roche Ltd - Geographic focus
- Exhibit 74: F. Hoffmann-La Roche Ltd - Segment focus
- Exhibit 75: F. Hoffmann-La Roche Ltd - Key offerings
- Exhibit 76: F. Hoffmann-La Roche Ltd - Key customers
- Exhibit 77: Merck & Co., Inc. - Vendor overview
- Exhibit 78: Merck & Co., Inc. - Business segments
- Exhibit 79: Merck & Co., Inc. - Organizational developments
- Exhibit 80: Merck & Co., Inc. - Geographic focus
- Exhibit 81: Merck & Co., Inc. - Segment focus
- Exhibit 82: Merck & Co., Inc. - Key offerings
- Exhibit 83: Merck & Co., Inc. - Key customers
- Exhibit 84: Sanofi - Vendor overview
- Exhibit 85: Sanofi - Business segments
- Exhibit 86: Sanofi - Organizational developments
- Exhibit 87: Sanofi - Geographic focus
- Exhibit 88: Sanofi - Segment focus
- Exhibit 89: Sanofi - Key offerings
- Exhibit 90: Sanofi - Key customers
- Exhibit 91: Validation techniques employed for market sizing
比較リスト
